Cullinan Therapeutics (CGEM) Common Equity (2020 - 2026)

Cullinan Therapeutics' Common Equity history runs 7 years deep, the most recent figure standing at $366.2 million for Q1 2026.

• In Q1 2026, Common Equity fell 33.65% year-over-year to $366.2 million; the TTM figure through Mar 2026 stood at $366.2 million (down 33.65% YoY), while the FY2025 annual figure was $408.7 million, down 30.76% from the prior year.
• Common Equity for Q1 2026 stood at $366.2 million, down from $408.7 million in the prior quarter.
• The five-year high for Common Equity was $656.2 million in Q2 2024, with the low at $366.2 million in Q1 2026.
• The 5-year median for Common Equity is $492.1 million (2025), against an average of $507.3 million.
• The sharpest annual moves came in 2024 and 2026: Common Equity soared 33.92% in 2024, then slumped 33.65% in 2026.
• Cullinan Therapeutics' Common Equity stood at $535.0 million in 2022, then dropped by 15.16% to $453.9 million in 2023, then jumped by 30.06% to $590.3 million in 2024, then tumbled by 30.76% to $408.7 million in 2025, then decreased by 10.41% to $366.2 million in 2026.
• Business Quant data shows CGEM's Common Equity at $366.2 million in Q1 2026, $408.7 million in Q4 2025, and $451.4 million in Q3 2025.